title: Bypass of DNA lesions generated during anticancer treatment with cisplatin by DNA polymerase eta.
abstract: DNA polymerase eta (Pol eta) is a eukaryotic lesion bypass polymerase that helps organisms to survive exposure to ultraviolet (UV) radiation, and tumor cells to gain resistance against cisplatin-based chemotherapy. It allows cells to replicate across cross-link lesions such as 1,2-d(GpG) cisplatin adducts (Pt-GG) and UV-induced cis-syn thymine dimers. We present structural and biochemical analysis of how Pol eta copies Pt-GG-containing DNA. The damaged DNA is bound in an open DNA binding rim. Nucleotidyl transfer requires the DNA to rotate into an active conformation, driven by hydrogen bonding of the templating base to the dNTP. For the 3'dG of the Pt-GG, this step is accomplished by a Watson-Crick base pair to dCTP and is biochemically efficient and accurate. In contrast, bypass of the 5'dG of the Pt-GG is less efficient and promiscuous for dCTP and dATP as a result of the presence of the rigid Pt cross-link. Our analysis reveals the set of structural features that enable Pol eta to replicate across strongly distorting DNA lesions.
authors.affiliation: Munich Center for Integrated Protein Science (CiPS), Ludwig Maximilians University, D-81377 Munich, Germany.
authors.forename: Aaron
authors.initials: A
authors.lastname: Alt
authors.forename: Katja
authors.initials: K
authors.lastname: Lammens
authors.forename: Claudia
authors.initials: C
authors.lastname: Chiocchini
authors.forename: Alfred
authors.initials: A
authors.lastname: Lammens
authors.forename: J Carsten
authors.initials: JC
authors.lastname: Pieck
authors.forename: David
authors.initials: D
authors.lastname: Kuch
authors.forename: Karl-Peter
authors.initials: KP
authors.lastname: Hopfner
authors.forename: Thomas
authors.initials: T
authors.lastname: Carell
mesh_terms: D000970:Antineoplastic Agents / Q000378:metabolism / Q000494:pharmacology*; D020029:Base Pairing; D001665:Binding Sites; D002945:Cisplatin / Q000031:analogs & derivatives / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology*; D003460:Crystallization; D018360:Crystallography, X-Ray; D004247:DNA / Q000737:chemistry / Q000378:metabolism*; D018736:DNA Adducts / Q000737:chemistry / Q000378:metabolism*; D004249:DNA Damage; D004261:DNA Replication; D004259:DNA-Directed DNA Polymerase / Q000737:chemistry / Q000235:genetics / Q000378:metabolism*; D003845:Deoxycytosine Nucleotides / Q000737:chemistry / Q000378:metabolism; D006860:Hydrogen Bonding; D008958:Models, Molecular; D016297:Mutagenesis, Site-Directed; D009690:Nucleic Acid Conformation; D011487:Protein Conformation; D017434:Protein Structure, Tertiary; D013698:Templates, Genetic; D000099270:Y-Family DNA Polymerases
chemical_list: D000970:Antineoplastic Agents; D002945:Cisplatin; D004247:DNA; D018736:DNA Adducts; D004259:DNA-Directed DNA Polymerase; D003845:Deoxycytosine Nucleotides; C057270:cisplatin-DNA adduct; C071963:cisplatin-guanosine adduct; C024107:2'-deoxycytidine 5'-triphosphate; C112338:Rad30 protein; D000099270:Y-Family DNA Polymerases